ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in San Antonio, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Colorectal Cancer
Squamous Cell Carcinoma of Head and Neck
Carcinoma
Neoplasm Metastasis

Non-Small-Cell Lung Cancer trials near San Antonio, TX, USA:

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (LIVIGNO-4)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mort...

Enrolling
Non-Small Cell Lung Cancer
Drug: Carboplatin
Drug: Livmoniplimab

Phase 2, Phase 3

AbbVie
AbbVie

San Antonio, Texas, United States and 60 other locations

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

San Antonio, Texas, United States and 254 other locations

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung ...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Pemetrexed/Carboplatin
Drug: Pemetrexed/Cisplatin

Phase 3

AstraZeneca
AstraZeneca

San Antonio, Texas, United States and 152 other locations

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC)....

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

San Antonio, Texas, United States and 30 other locations

Locations recently updated

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung C...

Enrolling
Non-Small Cell Lung Cancer
Drug: Pemetrexed
Drug: Carboplatin

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

San Antonio, Texas, United States and 183 other locations

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Drug: Datopotamab Deruxtecan
Drug: Pembrolizumab

Phase 3

Daiichi Sankyo
Daiichi Sankyo

San Antonio, Texas, United States and 243 other locations

Locations recently updated

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (HORIZON 1)

status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging sy...

Enrolling
Non-Small Cell Lung Cancer
Drug: Durvalumab
Drug: Entrectinib

Phase 3

Roche
Roche

San Antonio, Texas, United States and 181 other locations

Locations recently updated

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

(sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypo...

Enrolling
Non-small Cell Lung Cancer
NSCLC
Drug: Paclitaxel
Biological: Pembrolizumab

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

San Antonio, Texas, United States and 199 other locations

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Enrolling
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Drug: ABP 234
Drug: Pembrolizumab (EU)

Phase 3

Amgen
Amgen

San Antonio, Texas, United States and 216 other locations

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Platinum based chemotherapy
Device: NovoTTF-200T

Phase 3

NovoCure
NovoCure

San Antonio, Texas, United States and 88 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems